HIV/FIV protease inhibitors having a small P3 residue
US6803466B1 · kind B1 · utility
1Cited by
8References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 8, 2000 |
| Grant date | Oct 12, 2004 |
| Priority date | — |
| Expiry date | Jun 8, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
With the help of X-ray structural analyses of drug-resistant HIV proteases and molecular modeling, a new type of inhibitor with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant mutants, as well as FIV. Modification of existing HIV protease inhibitors effective against the wild type and drug-resistant mutants and further supports that FIV protease is a useful model for drug-resistant HIV proteases, which often are developed through reduction in size of the binging region for the P3 group or the combined P3 and P1 groups.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.